Clearside Biomedical shareholders approve doubling authorized common stock to 200M shares

Clearside Biomedical, Inc.

Shareholders approved amendment to increase authorized common shares from 100M to 200M (32.6M for, 4.4M against, 6.0M abstain).
Directors George Lasezkay and Christy Shaffer elected with 25.9M and 24.8M votes for, respectively.
Advisory vote on executive compensation passed with 27.6M for, 3.0M against; annual frequency chosen.
Ratification of Ernst & Young as auditor for FY2022 received 42.9M votes for, 88.8K against.
Annual meeting turnout: 43.0M of 60.2M shares represented (71.55% quorum).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.